ABVE-PC
Checked 2026-09-09
Children and adolescents with intermediate- and high-risk Hodgkin lymphoma in Children's Oncology Group trials, response-adapted with or without radiotherapy
Also called ABVE-PC, ABVE.
One cycle
every 21 days × 4-5 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 25 mg/m² | IV | D1, 2 | |
Bleomycin Glycopeptide antibiotic (DNA-cleaving) | 5 units/m² day 1, 10 units/m² day 8 | IV | D1, 8 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.4 mg/m² (maximum 2.8 mg) | IV | D1, 8 | |
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 125 mg/m² | IV | D1-3 | |
Prednisone Glucocorticoid | 40 mg/m² per day | Oral | D1-7 | |
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 800 mg/m² | IV | D1 |
Cycles
4-5
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Recommended
Notes
- AHOD0031 showed that rapid early responders with a complete response can omit radiotherapy without loss of event-free survival.
- Brentuximab vedotin replaces bleomycin in the successor regimen Bv-AVE-PC (AHOD1331).
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
ABVD
Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage
every 28 days × 2-6
BV-AVD
Stage III-IV classical Hodgkin lymphoma
every 28 days × 6
N-AVD (nivolumab + AVD)
Stage III-IV classical Hodgkin lymphoma, age 12 and above
every 28 days × 6
ICE
Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)
every 14 days × 2-3
Escalated BEACOPP
Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles
every 21 days × 4-6
MOPP
Historical: the first curative combination chemotherapy for advanced Hodgkin lymphoma (1960s to 1980s), replaced by ABVD
every 28 days × 6
Stanford V
Historical 12-week regimen with consolidative radiotherapy for advanced Hodgkin lymphoma; not superior to ABVD in the US Intergroup E2496 trial
every 28 days × 3
OEPA (vincristine, etoposide, prednisone, doxorubicin)
Induction for children and adolescents with Hodgkin lymphoma in the European EuroNet-PHL protocols; OPPA (procarbazine instead of etoposide) was the earlier version used in girls
every 28 days × 2